DW 1350

Drug Profile

DW 1350

Alternative Names: DW-1350

Latest Information Update: 12 Dec 2013

Price : $50

At a glance

  • Originator Dong Wha Pharmaceutical
  • Developer Actavis Inc; Dong Wha Pharmaceutical
  • Class Benzamidines; Osteoporosis therapies; Small molecules; Thiazoles
  • Mechanism of Action Bone resorption factor inhibitors; Leukotriene B4 receptor antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble
  • 01 Apr 2008 DW 1350 licensed to Teijin Pharna in Japan for the treatment of any indications, including Osteroporosis
  • 01 Apr 2008 Preclinical trials in Osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top